Pretreatment Staging FDG PET-Derived Radiomic Score Predicts Progression-Free Survival in Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy
Diagnostics · 22.07.2026 · 16 (14) · 2294
DOI: 10.3390/diagnostics16142294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 22.07.2026. Verfasst von Kadir Alper Kucuker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Izmir Katip Celebi University, 35360 Izmir, Turkey. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Clinical outcomes in locally advanced rectal cancer (LARC) treated with total neoadjuvant therapy (TNT) remain heterogeneous, and available clinicopathological parameters provide limited prognostic accuracy. This study aimed to develop a radiomic score (RadScore) from baseline staging 18F-FDG PET/CT images using LASSO-penalized Cox regression, and to evaluate its ability to independently predict progression-free survival (PFS) in LARC patients treated with TNT followed by surgery.
Methods
Eighty-five patients with LARC who underwent surgical resection after TNT between May 2018 and December 2024 were retrospectively analyzed. Primary tumor volumes were semi-automatically segmented on pretreatment FDG PET/CT images, and 140 radiomic features were extracted in accordance with Image Biomarker Standardisation Initiative (IBSI) guidelines. After correlation-based filtering, 23 non-redundant features were subjected to five-fold cross-validated LASSO-Cox regression for feature selection and RadScore construction. Internal validation used 1000-repetition bootstrap resampling.
Results
Disease progression was recorded in 33 of 85 patients (mean PFS: 57.5 months). The final RadScore comprised two features—Intensity Histogram Kurtosis and GLCM Difference Entropy—and was identified as an independent prognostic factor in multivariable Cox analysis (HR = 1.81; 95% CI: 1.23–2.67; p = 0.003). The model achieved a C-index of 0.674, with a bootstrap-corrected C-index of 0.650 (95% CI: 0.568–0.741). Kaplan–Meier analysis demonstrated significantly shorter PFS in the high-risk group (log-rank p = 0.006).
Conclusions
A pretreatment FDG PET-derived RadScore independently predicts PFS in LARC patients treated within a TNT framework, offering preliminary evidence for a potential imaging biomarker for preoperative risk stratification and individualized treatment planning—to our knowledge, among the first such evidence in a TNT-treated rectal cancer cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Izmir Katip Celebi University, 35360 Izmir, Turkey.
- Department of Radiation Oncology, Izmir Katip Celebi University, 35360 Izmir, Turkey.
- Department of Medical Oncology, Izmir Katip Celebi University, 35360 Izmir, Turkey.
ORCID-Profile: Kadir Alper Kucuker, Onder Kaan Vezir, Aysegul Aksu
Zitieren
APA
Kucuker, K. A., Vezir, O. K., Aksu, A., Sengul, A., Alacacioglu, A., & Turgut, B. (2026). Pretreatment Staging FDG PET-Derived Radiomic Score Predicts Progression-Free Survival in Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy. Diagnostics, 16(14), 2294. https://doi.org/10.3390/diagnostics16142294
Vancouver
Kucuker KA, Vezir OK, Aksu A, Sengul A, Alacacioglu A, Turgut B. Pretreatment Staging FDG PET-Derived Radiomic Score Predicts Progression-Free Survival in Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy. Diagnostics. 2026;16(14):2294. doi:10.3390/diagnostics16142294
BibTeX
@article{Kucuker2026,
author = {Kucuker, Kadir Alper and Vezir, Onder Kaan and Aksu, Aysegul and Sengul, Adem and Alacacioglu, Ahmet and Turgut, Bulent},
title = {Pretreatment Staging FDG PET-Derived Radiomic Score Predicts Progression-Free Survival in Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {14},
pages = {2294},
doi = {10.3390/diagnostics16142294}
}
EUVIMED